<DOC>
	<DOCNO>NCT01251120</DOCNO>
	<brief_summary>This randomize , open-label , parallel-group study assess effect disease remission RoActemra/Actemra ( tocilizumab ) combination disease-modifying antirheumatic drug ( DMARDs ) versus current best practice non-biologic DMARD therapy patient moderate-to-severe active rheumatoid arthritis . Patients randomly assign RoActemra/Actemra treatment group receive 8 mg/kg RoActemra/Actemra intravenously every 4 week . The anticipated time study treatment 12 month .</brief_summary>
	<brief_title>A Study RoActemra/Actemra ( Tocilizumab ) Combination With DMARDs Versus Current Best Practice DMARD Therapy Patients With Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Antirheumatic Agents</mesh_term>
	<criteria>Adult patient , age 18 year Diagnosis moderatetosevere active early rheumatoid arthritis ( RA ) less 2 year duration DAS28 &gt; 3.2 Swollen joint count ( SJC ) &gt; /=6 ( 66 joint count ) , tender joint count ( TJC ) &gt; /=6 ( 68 joint count ) Patients receive DMARDs ( include methotrexate ) 37 month Major surgery ( include joint surgery ) within 8 week prior screen plan major surgery within 6 month baseline Rheumatic autoimmune disease rheumatoid arthritis ( secondary Sj√∂grens syndrome nodulosis RA permit ) Functional class III IV define ACR Classification Functional Status Rheumatoid Arthritis Prior history current inflammatory joint disease RA</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2014</verification_date>
</DOC>